MELBOURNE, Australia, Sept. 11, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that primary results from its Phase III ZIRCON^[1] trial have been published in The Lancet Oncology, reporting that Telix's first-in-class investigational PET^[2] agent, TLX250-CDx (Zircaix®^[3], ⁸⁹Zr-girentuximab), is highly accurate in detecting and characterising clear cell renal cell carcinoma (ccRCC) in patients with indeterminate renal masses (IRMs).